A new, peer-reviewed paper in Optometry and Vision Science supports that myopia control gains with CooperVision’s MiSight^® 1 day* dual-focus soft contact lenses are sustained after treatment, with post-treatment  eye growth aligning with that of untreated, age-matched populations.¹ Publication of the seven-year study further validates the use of virtual control groups for rigorous myopia control research while further strengthening support for treating children with MiSight^® 1 day.

Eye Growth and Myopia Progression Following Cessation of Myopia Control Therapy with a Dual-Focus Soft Contact Lens¹ (Chamberlain P et al.) is now accessible via Open Access. 

The study followed subjects who had completed the six-year MiSight^® 1 day clinical trial—both the cohort who wore MiSight^® 1 day for all six years and the cohort who switched from the single vision to the MiSight^® 1 day lens for the final three years—for an additional year following treatment cessation. The results indicated that there is no rebound effect with MiSight^® 1 day contact lenses.  After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the12 months after treatment ceased. ^†2,3

“Eye care professionals (ECPs) have embraced the importance of myopia control in children, and we are starting to see this reflected in prescribing behaviour around the world,” said Paul Chamberlain, Senior Director of Research Programs at CooperVision and the paper’s lead author. “To turn the tide on childhood myopia, ECPs must be confident in an intervention that not only slows progression^‡4 but makes long-term treatment worthwhile. MiSight^® 1 day clearly demonstrates these benefits, allowing ECPs to prescribe with confidence for both immediate and lasting impact.”

By utilizing virtual control groups based on myopic children of the same age as those observed in year seven of this study, The new paper also provides the most robust validation to date of this model for assessing long-term myopia control outcomes. Investigators applied the model to the study’s preliminary outcomes data, first shared in 2021, and subsequently found their initial conclusions to be highly accurate.

This publication joins the previously published results of the study, joining the widely-cited three-year and six-year results,^4,5 all of which are published in Optometry and Vision Science, the journal of the American Academy of Optometry.

For more information on the study and MiSight^® 1 day, visit CooperVision.ca.

___________________________________________

* Regulatory indications of and access to interventions for slowing myopia progression vary by country. CooperVision does not endorse off-label prescribing. Canadian Indications for Use: MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

† Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates. Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight 1 day.

‡ Compared to single vision lens, no clinically meaningful change in refractive error (-0.25D or less from baseline). Fitted at 8-12 years of age.

References

1. Chamberlain, P, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. Optom and Vis Sci. 2025 Mar 25; ():10.1097/OPX.0000000000002244.

2. Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.

3. Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.

4. Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-572.

5. Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci. 2022 Mar 1;99(3):204-212.

Click HERE for the press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!